{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T14:03:45Z","timestamp":1793714625308,"version":"4.6.1"},"reference-count":97,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T00:00:00Z","timestamp":1782000000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T00:00:00Z","timestamp":1782000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["RNA Biology"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/15476286.2026.2689117","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T04:39:42Z","timestamp":1782103182000},"page":"1-17","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["FDA-approved antisense oligonucleotide therapies for duchenne muscular dystrophy: current status and future outlook"],"prefix":"10.1080","volume":"23","author":[{"given":"Hidenori","family":"Moriyama","sequence":"first","affiliation":[{"name":"University of Alberta","place":["Edmonton, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiori","family":"Moriyama","sequence":"additional","affiliation":[{"name":"Tokyo Metropolitan Children\u2019s Medical Center","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Yokota","sequence":"additional","affiliation":[{"name":"University of Alberta","place":["Edmonton, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,6,21]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-020-01430-8"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(88)90383-2"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/jhg.2010.49"},{"issue":"7","key":"e_1_3_4_5_1","doi-asserted-by":"crossref","first-page":"s73","DOI":"10.1016\/S0929-693X(25)00246-5","article-title":"Genetics and pathophysiology of Duchenne muscular dystrophy","volume":"32","author":"Amthor H","year":"2025","unstructured":"Amthor H, Avril A, Leturcq F. Genetics and pathophysiology of Duchenne muscular dystrophy. Arch Pediatr. 2025;32(7s1):s73\u2013s79.","journal-title":"Arch Pediatr"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.3331"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-020-00613-8"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70271-6"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2025.125331"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00036-X"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26755"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000213604"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2021.1992382"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-020-0075-7"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-020-0156-6"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/genes15111489"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/humu.22758"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrg1180"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2006.061"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70211-X"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60756-3"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23982"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24555"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S97635"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-210643"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.16437"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2016.0657"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2016.188"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-170272"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27662"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-200548"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-210665"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-180351"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.28075"},{"key":"e_1_3_4_35_1","unstructured":"ClinicalTrials.gov. A long-term observational study evaluating eteplirsen golodirsen or casimersen in routine clinical practice (EVOLVE). Available from: https:\/\/clinicaltrials.gov\/study\/NCT06606340"},{"key":"e_1_3_4_36_1","unstructured":"ClinicalTrials.gov. A study to compare safety and efficacy of high doses of eteplirsen in participants with Duchenne muscular dystrophy (DMD) (MIS51ON). 2025. https:\/\/clinicaltrials.gov\/study\/NCT03992430"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-180357"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001025"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195850"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.07.014"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2008.287"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009233"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2021.0043"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-020-01106-1"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1089\/nat.2020.0845"},{"key":"e_1_3_4_46_1","unstructured":"ClinicalTrials.gov. Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in participants with Duchenne muscular dystrophy (DMD) (ESSENCE). 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02500381"},{"key":"e_1_3_4_47_1","unstructured":"Parent Project Muscular Dystrophy. Sarepta announces completion of ESSENCE trial for exon 45 & 53 skipping therapies [Internet]. 2025. Available from: https:\/\/www.parentprojectmd.org\/sarepta-announces-completion-of-essence-trial-for-exon-45-53-skipping-therapies\/"},{"key":"e_1_3_4_48_1","unstructured":"Sarepta Therapeutics. Efficacy and safety of golodirsen and casimersen compared with placebo in Duchenne muscular dystrophy (ESSENCE): Phase 3 topline results. 2026. Available from: https:\/\/investorrelations.sarepta.com\/static-files\/0c18bee2-a0d3-41e7-b0d3-3d9b90b9129b"},{"key":"e_1_3_4_49_1","unstructured":"Sarepta Therapeutics. Sarepta Therapeutics announces positive data from Part B of MOMENTUM a Phase 2 study of SRP-5051 in patients with Duchenne muscular dystrophy amenable to skipping exon 51. 2024. Available from: https:\/\/investorrelations.sarepta.com\/node\/23111\/pdf"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2018.09.017"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan0713"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01339-3"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51235"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.1264"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-220811"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-221656"},{"key":"e_1_3_4_57_1","unstructured":"ClinicalTrials.gov. Long-term use of viltolarsen in boys with Duchenne muscular dystrophy in clinical practice (VILT-502). 2022. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04687020"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-70783-y"},{"key":"e_1_3_4_59_1","unstructured":"NS Pharma. NS Pharma shares preliminary results of viltolarsen (NS-065\/NCNP-01) phase 3 clinical trial (RACER53 study). 2024. Available from: https:\/\/www.nspharma.com\/ns-pharma-shares-preliminary-results-of-viltolarsen-ns-065-ncnp-01-phase-3-clinical-trial-racer53-study\/"},{"key":"e_1_3_4_60_1","unstructured":"ClinicalTrials.gov. Study to assess the safety and efficacy of viltolarsen in ambulant boys with DMD RACER53\u2013X. 2024. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04768062"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27347"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01512-2"},{"key":"e_1_3_4_63_1","unstructured":"U.S. Food & Drug Administration. 2021. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/213026lbl.pdf"},{"key":"e_1_3_4_64_1","unstructured":"ClinicalTrials.gov. Two-part study for dose determination of vesleteplirsen (SRP-5051) (part A) then dose expansion (part B) in participants with Duchenne muscular dystrophy amenable to exon 51-skipping treatment (MOMENTUM). 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04004065"},{"key":"e_1_3_4_65_1","unstructured":"Sarepta Therapeutics. Community letter: update SRP-5051 program. 2024. Available from: https:\/\/www.sarepta.com\/community-letter-update-srp-5051-program"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.06.036"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamem.2010.02.012"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.crtox.2024.100182"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2024.07.285"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000203724"},{"key":"e_1_3_4_71_1","unstructured":"ClinicalTrials.gov. A study of PGN-EDO51 in participants with Duchenne muscular dystrophy amenable to exon 51-skipping treatment (CONNECT1-EDO51). 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06079736"},{"key":"e_1_3_4_72_1","unstructured":"PepGen. PepGen to focus on development of promising DM1 program following 10 mg\/kg PGN-EDO51 update [Internet]. 2025. Available from: https:\/\/investors.pepgen.com\/node\/8941\/pdf"},{"key":"e_1_3_4_73_1","unstructured":"ClinicalTrials.gov. A study in participants with Duchenne muscular dystrophy amenable to exon 44 skipping to evaluate the safety and efficacy of ENTR-601\u201344 (ELEVATE-44). 2026. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07037862"},{"key":"e_1_3_4_74_1","unstructured":"Entrada Therapeutics. Entrada Therapeutics announces positive topline results from cohort 1 of participants with Duchenne muscular dystrophy treated with ENTR-601-44 in phase 1\/2 ELEVATE-44-201 study [Internet]. 2026. Available from: https:\/\/ir.entradatx.com\/news-releases\/news-release-details\/entrada-therapeutics-announces-positive-topline-results-cohort-1"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-026-00621-5"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaf241"},{"key":"e_1_3_4_77_1","unstructured":"ClinicalTrials.gov. Study of AOC 1044 in healthy adult volunteers and participants with Duchenne muscular dystrophy (DMD) mutations amenable to exon 44 skipping (EXPLORE44). 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05670730"},{"key":"e_1_3_4_78_1","unstructured":"ClinicalTrials.gov. Ph2 open-label study of AOC 1044 in Duchenne muscular dystrophy participants with mutations amenable to exon44 skipping (EXPLORE44OLE). 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06244082"},{"key":"e_1_3_4_79_1","unstructured":"ClinicalTrials.gov. Safety tolerability pharmacodynamic efficacy and pharmacokinetic study of DYNE-251 in participants with Duchenne muscular dystrophy amenable to exon 51 skipping (DELIVER). 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05524883"},{"key":"e_1_3_4_80_1","unstructured":"Dyne Therapeutics. Dyne Therapeutics announces initiation of Phase 3 FORZETTO trial of z-rostudirsen in Duchenne muscular dystrophy (DMD) ahead of planned BLA submission for U.S. accelerated approval [Internet]. 2026. Available from: https:\/\/investors.dyne-tx.com\/node\/12211\/pdf"},{"key":"e_1_3_4_81_1","unstructured":"ClinicalTrials.gov. Efficacy safety and tolerability of Zeleciment Rostudirsen (DYNE-251) administered intravenously every 4\u00a0weeks in ambulatory participants with Duchenne muscular dystrophy (FORZETTO). 2026. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07608432"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2023.06.022"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells14171326"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10974-024-09688-2"},{"key":"e_1_3_4_85_1","unstructured":"ClinicalTrials.gov. Safety and tolerability of WVE-210201 in patients with Duchenne muscular dystrophy. 2019. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03508947"},{"key":"e_1_3_4_86_1","unstructured":"ClinicalTrials.gov. Efficacy and safety study of WVE-210201 (Suvodirsen) with open-label extension in ambulatory patients with Duchenne muscular dystrophy. Dystance 2021;15. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03907072"},{"key":"e_1_3_4_87_1","unstructured":"ClinicalTrials.gov. Open-label study of WVE-N531 in patients with Duchenne muscular dystrophy (FORWARD-53). 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04906460"},{"key":"e_1_3_4_88_1","unstructured":"Wave Life Sciences. Wave Life Sciences announces positive data from FORWARD-53 clinical trial in DMD including significant functional benefit and reversal of muscle damage after 48 weeks of dosing with WVE-N531 [Internet]. Cambridge (MA): Wave Life Sciences; 2025 Mar 26 [cited 2026 Jun 19]. Available from: https:\/\/ir.wavelifesciences.com\/node\/12066\/pdf"},{"key":"e_1_3_4_89_1","unstructured":"ClinicalTrials.gov. Phase 1\/2a for safety PK and PD of SQY51 in paediatric and adult patients Duchenne muscular dystrophy (AVANCE1). 2024. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05753462"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.04.038"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.3390\/genes16070777"},{"issue":"2","key":"e_1_3_4_92_1","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1038\/mtna.2014.76","article-title":"Long-term efficacy of systemic multiexon skipping targeting dystrophin exons 45\u201355 with a cocktail of vivo-morpholinos in mdx52 mice","volume":"4","author":"Echigoya Y","year":"2015","unstructured":"Echigoya Y, Aoki Y, Miskew B, et al. Long-term efficacy of systemic multiexon skipping targeting dystrophin exons 45\u201355 with a cocktail of vivo-morpholinos in mdx52 mice. Mol Ther Nucleic Acids. 2015;4(2):e225.","journal-title":"Mol Ther Nucleic Acids"},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.07.012"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm8040041"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-025-00561-6"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.53094"},{"key":"e_1_3_4_97_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-024-01059-3"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2025.106221"}],"container-title":["RNA Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/15476286.2026.2689117","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/15476286.2026.2689117","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/15476286.2026.2689117","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T04:40:09Z","timestamp":1782103209000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/15476286.2026.2689117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,21]]},"references-count":97,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/15476286.2026.2689117"],"URL":"https:\/\/doi.org\/10.1080\/15476286.2026.2689117","relation":{},"ISSN":["1547-6286","1555-8584"],"issn-type":[{"value":"1547-6286","type":"print"},{"value":"1555-8584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,21]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=krnb20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=krnb20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-06-09","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}